Tag: cemiplimab
FDA approves Regeneron, Sanofi skin cancer immuno-oncology drug
The drug is the first FDA-approved treatment for patients with advanced forms of a skin cancer known as cutaneous squamous cell carcinoma.
European agency to review Regeneron-Sanofi drug applications
The European agency will also review the marketing authorization application for cemiplimab, which is used to treat patients with metastatic cutaneous squamous cell carcinoma.
Regeneron collaborates with Dutch company on combined cancer treatment
Regeneron in the agreement has an option to exclusively license an ISA Pharmaceuticals drug that targets cancers linked to a human papilloma virus.
